What actually changed in testosterone therapy.
We track the trials, guideline revisions, and regulatory filings that actually change how testosterone is prescribed — and translate them without the hype or the panic.
EAU 2026 hypogonadism guidelines — SHBG and calculated free T get formalized, the 12 nmol/L threshold stays, prostate cancer guidance is significantly revised
The European Association of Urology's 2026 update, published August 10, formally expands SHBG and calculated free testosterone into everyday diagnosis, preserves the 12 nmol/L (~346 ng/dL) total T threshold, and significantly revises the prostate cancer subsection — including a strict one-year post-prostatectomy PSA < 0.01 ng/mL threshold before TRT can be considered.
FDA proposes biggest TRT label change since 2015 — age limit gone, prostate cancer language narrowed, BPH warning revised
HHS and the FDA formally requested class-wide TRT label updates on June 18, 2026: remove the age-related hypogonadism limitation, narrow the prostate cancer contraindication to metastatic disease only, and revise the BPH warning. Here's what has actually changed — and what hasn't.
TRT StudiesOne year after TRAVERSE: what the trial changed in TRT prescribing
What the 5,246-patient RCT concluded, what caveats remain, and how it changed real prescribing.